allergic rhinitis (ar) is an ige-mediated upper airway disease with a high worldwide prevalence. Microrna (mir)-205-5p upregulation has been observed in ar; however, its role is poorly understood. The aim of the present study was to investigate the effect of mir-205-5p on AR-associated inflammation. To establish an AR model, BalB/c mice were sensitized using an intraperitoneal injection of ovalbumin (oVa) on days 0, 7 and 14, followed by intranasal challenge with oVa on days 21-27. a lentiviral sponge for mir-205-5p was used to downregulate mir-205-5p in vivo via intranasal administration on days 20-26. reverse transcription-quantitative Pcr revealed that mir-205-5p was upregulated in ar mice. notably, mir-205-5p knockdown reduced the frequency of nose-rubbing and sneezing, and attenuated pathological alterations in the nasal mucosa. The levels of total and OVA-specific IgE, cytokines IL-4, IL-5 and IL-13, and inflammatory cells, were decreased by miR-205-5p knockdown in ar mice. in addition, mir-205-5p knockdown inhibited nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation by reducing the expression levels of nlrP3, apoptosis associated speck like protein containing a card, cleaved caspase-1 and il-1β by western blot analysis. B-cell lymphoma 6 (BCL6) was confirmed as a target of miR-205-5p by luciferase reporter assay. In conclusion, the present findings suggested that mir-205-5p knockdown may attenuate the inflammatory response in AR by targeting BCL6, which may be a potential therapeutic target for ar.